BidaskClub upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX) from a hold rating to a buy rating in a research note issued to investors on Saturday morning, BidAskClub reports.

Other research analysts also recently issued reports about the stock. ValuEngine raised shares of Protagonist Therapeutics from a hold rating to a buy rating in a research report on Friday, March 6th. HC Wainwright reissued a buy rating and set a $28.00 price objective (up from $23.00) on shares of Protagonist Therapeutics in a research report on Wednesday, May 13th. Nomura Instinet raised their price objective on shares of Protagonist Therapeutics from $29.00 to $33.00 and gave the stock a buy rating in a research report on Monday, May 11th. SVB Leerink raised their price objective on shares of Protagonist Therapeutics from $17.00 to $30.00 and gave the stock an outperform rating in a research report on Friday, May 22nd. Finally, Nomura raised their price objective on shares of Protagonist Therapeutics from $29.00 to $33.00 and gave the stock a buy rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $26.92.

NASDAQ PTGX opened at $17.66 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.46 and a quick ratio of 3.46. The firm’s fifty day moving average price is $16.53 and its 200 day moving average price is $9.71. The company has a market capitalization of $508.64 million, a price-to-earnings ratio of -5.62 and a beta of 1.37. Protagonist Therapeutics has a 12 month low of $4.47 and a 12 month high of $19.67.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.03). The business had revenue of $3.65 million for the quarter, compared to the consensus estimate of $3.60 million. As a group, sell-side analysts forecast that Protagonist Therapeutics will post -2.39 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in PTGX. JPMorgan Chase & Co. lifted its stake in shares of Protagonist Therapeutics by 241.6% in the 1st quarter. JPMorgan Chase & Co. now owns 883,013 shares of the company’s stock worth $6,234,000 after acquiring an additional 624,546 shares during the period. FMR LLC lifted its stake in shares of Protagonist Therapeutics by 3.5% in the 4th quarter. FMR LLC now owns 4,080,967 shares of the company’s stock worth $28,771,000 after acquiring an additional 138,955 shares during the period. VR Adviser LLC acquired a new stake in shares of Protagonist Therapeutics in the 1st quarter worth $799,000. Invesco Ltd. acquired a new stake in shares of Protagonist Therapeutics in the 1st quarter worth $599,000. Finally, Ikarian Capital LLC lifted its stake in shares of Protagonist Therapeutics by 102.0% in the 1st quarter. Ikarian Capital LLC now owns 158,222 shares of the company’s stock worth $1,117,000 after acquiring an additional 79,896 shares during the period. Institutional investors own 85.62% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Article: What does an outperform rating mean?

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.